Today: 9 June 2026
Oracle stock slips as OpenAI funding update and insider sale filing keep AI spend in focus
31 December 2025
2 mins read

Oracle stock slips as OpenAI funding update and insider sale filing keep AI spend in focus

NEW YORK, December 31, 2025, 12:42 ET — Regular session

  • Oracle shares edged lower in midday trading, tracking softer U.S. tech.
  • Fresh OpenAI funding headlines kept attention on AI infrastructure spending.
  • A regulatory filing disclosed an Oracle executive’s share gift and sale.

Oracle Corp (ORCL) shares were down 0.3% at $196.60 in midday New York trading on Wednesday, after closing at $197.21 in the prior session. The stock traded between $195.08 and $197.49 so far in the regular session.

The weakness matched a modest pullback in U.S. technology shares, with the Nasdaq 100-tracking Invesco QQQ and the Technology Select Sector SPDR both down about 0.3%.

The drift matters because Oracle’s valuation has been tied closely to investor confidence in AI-driven cloud growth and the cost of building out data-center capacity. Scrutiny rose after Oracle’s latest quarterly outlook missed Wall Street estimates and pointed to pressure from higher spending, according to Reuters.

SoftBank Group said it completed a $41 billion investment in OpenAI, a funding round that would give the Japanese firm about an 11% stake, Reuters reported. OpenAI and Oracle, among other stakeholders, have planned a data-center initiative dubbed “Stargate,” with backing from major investors including SoftBank, Reuters added. Reuters

For Oracle shareholders, the OpenAI funding update is a reminder that the AI boom is increasingly about who can finance and build computing capacity, not just who can sell software. Traders have treated shifts in funding sentiment as a read-through for how quickly large AI projects can scale.

A filing showed Mark Hura, Oracle’s president of global field operations, gifted 5,000 shares on Dec. 22 and sold 15,000 shares on Dec. 24 at a weighted average price of about $196.89. The Form 4 showed he held 234,077 shares after the transactions, while a separate Form 144 notice listed the 15,000-share sale at roughly $3.0 million.

Form 4 is the U.S. disclosure insiders file when they buy, sell or transfer company stock. Form 144 is a notice of a proposed sale of restricted or control securities, and it can foreshadow supply in the market.

Oracle’s move came alongside losses in other cloud-heavy megacaps, with Microsoft down about 0.5% and Amazon off about 0.5%, while chipmaker Nvidia rose about 0.7%.

Competition signals also stayed in focus after Reuters reported Brookfield is starting a cloud business to lease chips inside data centers, citing The Information. Reuters said the move could add pressure on traditional cloud providers including Oracle, Microsoft and Amazon to sharpen energy logistics and capital efficiency.

On the macro front, U.S. weekly jobless claims fell to 199,000, the lowest since late November, in a report published early because of the New Year’s holiday. “The drop in initial unemployment claims to 199,000 in the week of Christmas was likely another seasonal-adjustment distortion,” John Ryding, chief economic adviser at Brean Capital, said; the Labor Department is due to publish December employment figures on Jan. 9. Reuters

That data will shape rate expectations heading into 2026, an important driver for growth stocks whose valuations depend heavily on future earnings. Investors are also watching whether AI data-center buildouts hit bottlenecks in power, permitting and supply chains — and how quickly that spending converts into revenue.

Oracle says its fiscal third-quarter results will be announced in mid-March 2026. Traders expect that update to refocus attention on cloud growth, spending levels and demand from large AI customers.

For now, Oracle shares remain near recent levels as year-end flows and AI infrastructure headlines set the tone. The next directional catalyst is likely to come from early-2026 economic data and any updates from Oracle or its biggest AI partners on the pace of data-center deployments.

Stock Market Today

  • J.M. Smucker Shares Rise After Earnings Beat Despite Sales Warning
    June 9, 2026, 10:05 AM EDT. J.M. Smucker shares rose 3.16% in pre-market trading after the company reported a 20% rise in adjusted earnings per share to $2.77, beating Wall Street estimates. The packaged-food firm grew net sales by 6% to $2.27 billion in Q4 but issued a cautionary note, forecasting a 3-4% decline in annual sales for fiscal 2027, below analysts' expectations of 1% growth. CEO Mark Smucker highlighted a focus on organic volume growth and profit improvement amid shifts in industry pricing strategies. Coffee sales drove quarterly results with a 12% retail sales increase but volume declines. The company flagged risks including consumer shifts to store brands, weight-loss drug impacts, and tariff fluctuations. Smucker's outlook balances lower sales with improved profitability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Premium Bonds January 2026 draw date is set — here’s when NS&I results drop and why savers are rethinking
Previous Story

Premium Bonds January 2026 draw date is set — here’s when NS&I results drop and why savers are rethinking

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Next Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Go toTop